• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BCTG Acquisition Corp.

    8/19/21 4:59:28 PM ET
    $BCTG
    Business Services
    Finance
    Get the next $BCTG alert in real time by email
    SC 13G 1 d8926024_sc13-g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

    Tango Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    87583X109
    (CUSIP Number)

     

     

    August 10, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

     

    CUSIP No 87583X109    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      5,487,910  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      5,487,910  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      5,487,910  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     

     
     

     

     

    CUSIP No 87583X109    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners Master Fund, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      5,487,910  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      5,487,910  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      5,487,910  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

     

     
     

     

     

    CUSIP No 87583X109    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      5,487,910  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      5,487,910  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      5,487,910  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     
     

     

     

    CUSIP No 87583X109    

     

    1. NAME OF REPORTING PERSONS  
         
      Eli Casdin  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      5,487,910  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      5,487,910  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      5,487,910  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     
     

     

     

    CUSIP No 87583X109    

     

    Item 1. (a). Name of Issuer:  
           
        Tango Therapeutics, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    100 Binney St., Suite 700

    Cambridge, Massachusetts 02142

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Casdin Capital, LLC

    Casdin Partners Master Fund, L.P.

    Casdin Partners GP, LLC

    Eli Casdin

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners Master Fund, L.P.

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners GP, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Eli Casdin

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

     

     

      (c). Citizenship:  
           
       

    Casdin Capital, LLC - Delaware

    Casdin Partners Master Fund, L.P. – Cayman Islands

    Casdin Partners GP, LLC - Delaware

    Eli Casdin– United States of America

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        87583X109  

     

     
     

     

     

     

    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    5,487,910 shares deemed beneficially owned by Casdin Capital, LLC

    5,487,910 shares deemed beneficially owned by Casdin Partners Master Fund, L.P.

    5,487,910 shares deemed beneficially owned by Casdin Partners GP, LLC

    5,487,910 shares deemed beneficially owned by Eli Casdin

     

      (b) Percent of class:
         
       

    6.3% deemed beneficially owned by Casdin Capital, LLC

    6.3% deemed beneficially owned by Casdin Partners Master Fund, L.P.

    6.3% deemed beneficially owned by Casdin Partners GP, LLC

    6.3% deemed beneficially owned by Eli Casdin

     

     
     

     

     

     

      (c) Number of shares as to which Casdin Capital, LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 5,487,910 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 5,487,910 .

     

      Number of shares as to which Casdin Partners Master Fund, L.P. has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 5,487,910 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 5,487,910 .

     

      Number of shares as to which Casdin Partners GP, LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 5,487,910 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 5,487,910 .

     

      Number of shares as to which Eli Casdin has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 5,487,910 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 5,487,910 .

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
       
     

     

     
     

     

     

     

    Item 6. Ownqership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     


    Item 8.
    Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        August 19, 2021  
        (Date)  

     

     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
     

    (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.*

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       

     

       
      /s/ Eli Casdin*
      Eli Casdin

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated August 19, 2021 relating to the Common Stock, par value $0.001 per share of Tango Therapeutics, Inc., shall be filed on behalf of the undersigned.

     

     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
     

    (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       

     

       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

    Get the next $BCTG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Boxer Capital, LLC claimed ownership of 6,973,166 units of Common Stock

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/20/21 4:30:38 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 3: BCTG Holdings, LLC claimed ownership of 6,988,450 units of Common Stock

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/20/21 4:31:02 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 4 filed by Beckman Daniella

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/16/21 7:00:32 PM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    SEC Filings

    View All

    SEC Form S-8 filed by BCTG Acquisition Corp.

    S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)

    10/14/21 5:30:07 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 424B3 filed by BCTG Acquisition Corp.

    424B3 - Tango Therapeutics, Inc. (0001819133) (Filer)

    10/7/21 8:18:28 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form EFFECT filed by BCTG Acquisition Corp.

    EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)

    9/30/21 12:15:16 AM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

    – Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "TNGX" – – Total expected cash position of approximately $515 million including gross proceeds from transaction totaling approximately $342 million, combining funds held in BCTG's trust account and PIPE financing once completed – CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango Therapeutics" or "Tango"), a biotechnology company committed to discovering and delivering the next generation of prec

    8/10/21 9:00:00 AM ET
    $BCTG
    Business Services
    Finance

    Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies

    - Leading institutional investors commit $186 million through a common stock private investment in public equity ("PIPE") led by Boxer Capital - Total proceeds expected to be approximately $353 million, combining funds held in trust by BCTG Acquisition Corp and the PIPE financing - Merger expected to be completed in third quarter of 2021, and Combined Company will be listed on Nasdaq under the ticker "TNGX" – - Joint investor conference call to discuss the proposed transaction today, Wednesday, April 14, at 10:00 a.m. ET – Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (NA

    4/14/21 8:30:00 AM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BCTG Acquisition Corp.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    9/10/21 12:17:18 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form SC 13D filed by BCTG Acquisition Corp.

    SC 13D - Tango Therapeutics, Inc. (0001819133) (Subject)

    8/20/21 4:31:07 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form SC 13G filed by BCTG Acquisition Corp.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    8/19/21 4:59:28 PM ET
    $BCTG
    Business Services
    Finance